April 23, 2025

Long-Term EEG Monitoring Now Authorized in the United States

The FDA has authorized Minder, the first implantable continuous electroencephalogram monitor, offering long-term brain activity tracking for improved epilepsy management, available in the U.S.

Conexiant

April 23, 2025

FDA Targets Petroleum-Based Dyes in Food Supply

The FDA and HHS announced plans to eliminate petroleum-based synthetic food dyes, citing potential health risks and aligning with global safety standards.

Conexiant

April 23, 2025

FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer

The FDA approved the combination of a PD-1 inhibitor and a CTLA-4 inhibitor for patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer ...

The ASCO Post

April 23, 2025

More Data, Please: FDA to Novavax

Novavax reveals FDA's request for more clinical data if COVID-19 vaccine is approved and expresses confidence in approval based on discussions.

Reuters

April 21, 2025

New Prescription App Reduces Migraine Days

The FDA has authorized CT-132, the first prescription digital therapeutic for episodic migraine prevention, based on clinical trial data showing reduced monthly migraine days.

Conexiant

April 18, 2025

FDA Approves New Spontaneous Urticaria Therapy

The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.

Conexiant

April 18, 2025

3 things you missed in government this week

ADA News is providing a roundup of three happenings in government that you may have missed this week.

ADA News

April 17, 2025

Oral Agent Shows Weight, A1c Drops

“As a convenient once-daily pill, orforglipron may provide a new option”—Lilly's oral GLP-1 agent showed up to 7.9% weight loss and HbA1c reductions in phase III diabetes trial.

Reuters

April 17, 2025

FDA Reviews Eylea HD for RVO

The agency has initiated priority review of the anti-VEGF agent as a treatment for macular edema secondary to retinal vein occlusion.

Ophthalmology Management